
## Jorge A GÃ<sup>3</sup>mez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/219649/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile. Human Vaccines and Immunotherapeutics, 2024, 17, 5603-5613.	1.4	3
2	Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 5-6.	0.7	0
3	Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants― Infectious Diseases and Therapy, 2022, , .	1.8	0
4	A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	0
5	Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 255-263.	0.7	2
6	Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants― Human Vaccines and Immunotherapeutics, 2021, , 1-3.	1.4	0
7	Herpes zoster epidemiology in Latin America: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0255877.	1.1	19
8	How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future. Journal of Market Access & Health Policy, 2020, 8, 1719588.	0.8	11
9	Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico― Human Vaccines and Immunotherapeutics, 2019, 15, 570-571.	1.4	0
10	Impact assessment of the incorporation of the rotavirus vaccine in the province of San Luis – Argentina. Epidemiology and Infection, 2019, 147, e308.	1.0	2
11	Estimation of the real burden of invasive meningococcal disease in Argentina. Epidemiology and Infection, 2019, 147, e311.	1.0	7
12	PIN16 ESTIMATED ANNUAL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IMMUNIZATION PROGRAM IN COLOMBIA (2011-2018). Value in Health Regional Issues, 2019, 19, S43.	0.5	2
13	Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil. Pediatric Infectious Disease Journal, 2019, 38, e260-e265.	1.1	5
14	Estimación de la Relación Costo-Efectividad de las Vacunas Neumocócicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacunación de Población Infantil Mexicana. Value in Health Regional Issues, 2016, 11, 76-84.	0.5	6
15	Cost effectiveness evaluation of a rotavirus vaccination program in Argentina. Vaccine, 2015, 33, 5684-5690.	1.7	8
16	Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: A multicountry analysis. Vaccine, 2010, 28, G14-G22.	1.7	12
17	Surveillance for rotavirus in Argentina. Journal of Medical Virology, 2001, 65, 190-198.	2.5	72
18	Surveillance for rotavirus in Argentina. Journal of Medical Virology, 2001, 65, 190-8.	2.5	27